Compare Incyte Corporation (INCY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Williams-Sonoma, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Williams-Sonoma, Inc. for 59 Days on average.
| INCY | WSM | |
|---|---|---|
Market Cap | $22.85B | $28.15B |
Volume | 1,927,029 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $251.81 |
52-Week Low | $83.80 | $168.64 |
Typical Hold Time | 33 Days | 59 Days |
Enterprise Value | $18.35B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, near its pivot point of $239 with bullish moving average signals. The company demonstrates strong profitability with a 14.73% net income margin and 54.96% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights market share gains and margin expansion through reduced discounting, with a new Pottery Barn collaboration and store openings fueling growth.
The outlook remains positive with a consensus price target of $246.31 offering 3% upside, though risks include housing market sensitivity and high valuation multiples. Earnings growth and disciplined cost control position WSM for continued outperformance, but investors should monitor competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
